PUBLISHER: Grand View Research | PRODUCT CODE: 1446548
PUBLISHER: Grand View Research | PRODUCT CODE: 1446548
The global dermatology imaging devices market size is anticipated to reach USD 5.60 billion by 2030 and it is projected to grow at a CAGR of 13.09% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of skin disorders such as cancer, and inflammatory dermatoses, among others are the major contributing factors for market growth. For instance, according to the International Agency for Research on Cancer, in 2022, globally 331, 722 cases of melanoma cancer were reported, the cases are further estimated to reach 1,262,756 by 2027. Furthermore, technological advancements are also expected to propel market growth.
Dermatology imaging devices are efficient as they provide non-invasive, high-resolution visualization of skin lesions and other related conditions. They help dermatologists by providing detailed morphology, structure, and traits of diverse skin abnormalities, which thereby help in precise diagnosis and treatment strategizing. Moreover, they enable remote consultation, assist specialists to exchange images and expertise, thereby enhancing patient care.
Technological advancements in dermatology imaging devices such as high-resolution images, integration with AI, 3D imaging are further expected to contribute to the market growth. For instance, ,in June 2023, FotoFinder Systems GmbH, a prominent manufacturer of medical imaging systems for dermatology, has recently unveiled two new cutting-edge innovations - the meesma, a portable imaging solution for aesthetics, and the fourth generation FotoFinder ATBM master equipped with an AI assistant called AIMEE for Total Body Dermoscopy. These state-of-the-art systems are showcased for the first time to experts at the "25th World Congress of Dermatology" (WCD) in Singapore, scheduled from 3rd to 8th July 2023.
Market participants are implementing a range of strategic initiatives to maintain competitiveness and expand their market share. These initiatives include product launch, government approval, expansion, partnership, merger, and acquisitions. In May 2023,Orlucent's skin fluorescence imaging system has been granted Breakthrough Device Designation (BDD) by the US Food and Drug Administration (FDA).t's a handheld point-of-care device that provides molecular-level imaging and analysis of moles. This innovative tool can identify and assess biological tissue-remodeling activity associated with the development of abnormal moles in adults, all without requiring invasive procedures.